Comprehensive Stock Comparison
Compare UiPath Inc. (PATH) vs Synopsys, Inc. (SNPS) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | SNPS | 15.1% revenue growth vs PATH's 9.3% |
| Value | PATH | Lower P/E (16.0x vs 28.7x) |
| Quality / Margins | PATH | 14.8% net margin vs SNPS's 13.8% |
| Stability / Safety | PATH | Beta 1.34 vs SNPS's 1.37, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | SNPS | -9.5% vs PATH's -12.8% |
| Efficiency (ROA) | PATH | 7.9% ROA vs SNPS's 2.3%, ROIC -11.8% vs 3.0% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
UiPath is a leading provider of robotic process automation (RPA) software that helps businesses automate repetitive digital tasks. The company generates revenue primarily through software licenses and cloud subscriptions — with its platform segment contributing roughly 80% of revenue — along with maintenance and support services. Its key competitive advantage lies in its comprehensive, AI-powered automation platform that combines process discovery, low-code development, and enterprise-grade management tools, creating significant switching costs for large enterprise customers.
Synopsys is a leading provider of electronic design automation software and semiconductor intellectual property used to design and test integrated circuits. The company generates revenue primarily from software license sales (~60% of revenue) and maintenance/services (~40%), with its IP segment—which includes interface, analog, and security IP—growing rapidly. Its competitive moat stems from deep technical expertise, long-standing customer relationships in the complex semiconductor design ecosystem, and high switching costs for its mission-critical tools.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
PATH leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). SNPS leads in 1 (Total Returns). 2 tied.
Financial Metrics (TTM)
SNPS is the larger business by revenue, generating $8.0B annually — 5.2x PATH's $1.6B. Profitability is closely matched — net margins range from 14.8% (PATH) to 13.8% (SNPS). On growth, SNPS holds the edge at +65.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | PATHUiPath Inc. | SNPSSynopsys, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $1.6B | $8.0B |
| EBITDAEarnings before interest/tax | $13M | $1.7B |
| Net IncomeAfter-tax profit | $230M | $1.1B |
| Free Cash FlowCash after capex | $312M | $2.3B |
| Gross MarginGross profit ÷ Revenue | +83.2% | +75.1% |
| Operating MarginEBIT ÷ Revenue | +0.6% | +10.8% |
| Net MarginNet income ÷ Revenue | +14.8% | +13.8% |
| FCF MarginFCF ÷ Revenue | +20.1% | +28.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +15.9% | +65.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +19.5% | -78.8% |
Valuation Metrics
| Metric | PATHUiPath Inc. | SNPSSynopsys, Inc. |
|---|---|---|
| Market CapShares × price | $797M | $79.3B |
| Enterprise ValueMkt cap + debt − cash | -$5M | $90.7B |
| Trailing P/EPrice ÷ TTM EPS | -82.54x | 51.49x |
| Forward P/EPrice ÷ next-FY EPS est. | 15.98x | 28.67x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.82x |
| EV / EBITDAEnterprise value multiple | — | 57.55x |
| Price / SalesMarket cap ÷ Revenue | 0.56x | 11.24x |
| Price / BookPrice ÷ Book value/share | 3.26x | 2.36x |
| Price / FCFMarket cap ÷ FCF | 2.61x | 58.75x |
Profitability & Efficiency
PATH delivers a 11.9% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $4 for SNPS. PATH carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to SNPS's 0.50x. On the Piotroski fundamental quality scale (0–9), PATH scores 5/9 vs SNPS's 3/9, reflecting solid financial health.
| Metric | PATHUiPath Inc. | SNPSSynopsys, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +11.9% | +3.6% |
| ROA (TTM)Return on assets | +7.9% | +2.3% |
| ROICReturn on invested capital | -11.8% | +3.0% |
| ROCEReturn on capital employed | -7.5% | +3.3% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 |
| Debt / EquityFinancial leverage | 0.04x | 0.50x |
| Net DebtTotal debt minus cash | -$801M | $11.4B |
| Cash & Equiv.Liquid assets | $880M | $2.9B |
| Total DebtShort + long-term debt | $78M | $14.3B |
| Interest CoverageEBIT ÷ Interest expense | — | 6.38x |
Total Returns (with DRIP)
A $10,000 investment in SNPS five years ago would be worth $16,288 today (with dividends reinvested), compared to $1,555 for PATH. Over the past 12 months, SNPS leads with a -9.5% total return vs PATH's -12.8%. The 3-year compound annual growth rate (CAGR) favors SNPS at 4.4% vs PATH's -10.2% — a key indicator of consistent wealth creation.
| Metric | PATHUiPath Inc. | SNPSSynopsys, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -32.4% | -13.8% |
| 1-Year ReturnPast 12 months | -12.8% | -9.5% |
| 3-Year ReturnCumulative with dividends | -27.7% | +13.8% |
| 5-Year ReturnCumulative with dividends | -84.4% | +62.9% |
| 10-Year ReturnCumulative with dividends | -84.4% | +825.1% |
| CAGR (3Y)Annualised 3-year return | -10.2% | +4.4% |
Risk & Volatility
PATH is the less volatile stock with a 1.34 beta — it tends to amplify market swings less than SNPS's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SNPS currently trades 63.5% from its 52-week high vs PATH's 54.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PATHUiPath Inc. | SNPSSynopsys, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.34x | 1.37x |
| 52-Week HighHighest price in past year | $19.84 | $651.73 |
| 52-Week LowLowest price in past year | $9.38 | $365.74 |
| % of 52W HighCurrent price vs 52-week peak | +54.1% | +63.5% |
| RSI (14)Momentum oscillator 0–100 | 36.0 | 42.9 |
| Avg Volume (50D)Average daily shares traded | 24.5M | 1.7M |
Analyst Outlook
Wall Street rates PATH as "Hold" and SNPS as "Buy". Consensus price targets imply 51.9% upside for PATH (target: $16) vs 27.9% for SNPS (target: $529).
| Metric | PATHUiPath Inc. | SNPSSynopsys, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $16.30 | $529.44 |
| # AnalystsCovering analysts | 24 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +49.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Apr 21 | Feb 26 | Change |
|---|---|---|---|
| UiPath Inc. (PATH) | 100 | 18.17 | -81.8% |
| Synopsys, Inc. (SNPS) | 100 | 187.04 | +87.0% |
Synopsys, Inc. (SNPS) returned +63% over 5 years vs UiPath Inc. (PATH)'s -84%. A $10,000 investment in SNPS 5 years ago would be worth $16,288 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| UiPath Inc. (PATH) | $336M | $1.4B | +325.3% |
| Synopsys, Inc. (SNPS) | $2.4B | $7.1B | +191.2% |
Synopsys, Inc.'s revenue grew from $2.4B (2016) to $7.1B (2025) — a 12.6% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| UiPath Inc. (PATH) | -154.7% | -5.2% | +96.7% |
| Synopsys, Inc. (SNPS) | 11.0% | 18.9% | +71.5% |
Synopsys, Inc.'s net margin went from 11% (2016) to 19% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Synopsys, Inc. (SNPS) | 96.9 | 58.4 | -39.7% |
Synopsys, Inc. has traded in a 30x–97x P/E range over 9 years; current trailing P/E is ~51x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| UiPath Inc. (PATH) | -1 | -0.13 | +87.0% |
| Synopsys, Inc. (SNPS) | 1.73 | 8.04 | +364.7% |
Synopsys, Inc.'s EPS grew from $1.73 (2016) to $8.04 (2025) — a 19% CAGR.
Chart 6Free Cash Flow — 5 Years
UiPath Inc. generated $306M FCF in 2025 (+1076% vs 2021). Synopsys, Inc. generated $1B FCF in 2025 (-3% vs 2021).
PATH vs SNPS: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is PATH or SNPS a better buy right now?
Synopsys, Inc. (SNPS) offers the better valuation at 51.5x trailing P/E (28.7x forward), making it the more compelling value choice. Analysts rate Synopsys, Inc. (SNPS) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PATH or SNPS?
On forward P/E, UiPath Inc. is actually cheaper at 16.0x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — PATH or SNPS?
Over the past 5 years, Synopsys, Inc. (SNPS) delivered a total return of +62.9%, compared to -84.4% for UiPath Inc. (PATH). A $10,000 investment in SNPS five years ago would be worth approximately $16K today (assuming dividends reinvested). Over 10 years, the gap is even starker: SNPS returned +825.1% versus PATH's -84.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PATH or SNPS?
By beta (market sensitivity over 5 years), UiPath Inc. (PATH) is the lower-risk stock at 1.34β versus Synopsys, Inc.'s 1.37β — meaning SNPS is approximately 2% more volatile than PATH relative to the S&P 500. On balance sheet safety, UiPath Inc. (PATH) carries a lower debt/equity ratio of 4% versus 50% for Synopsys, Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — PATH or SNPS?
Synopsys, Inc. (SNPS) is the more profitable company, earning 18.9% net margin versus -5.2% for UiPath Inc. — meaning it keeps 18.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SNPS leads at 13.0% versus -11.4% for PATH. At the gross margin level — before operating expenses — PATH leads at 82.7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is PATH or SNPS more undervalued right now?
On forward earnings alone, UiPath Inc. (PATH) trades at 16.0x forward P/E versus 28.7x for Synopsys, Inc. — 12.7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PATH: 51.9% to $16.30.
07Which pays a better dividend — PATH or SNPS?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is PATH or SNPS better for a retirement portfolio?
For long-horizon retirement investors, Synopsys, Inc. (SNPS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+825.1% 10Y return). Both have compounded well over 10 years (SNPS: +825.1%, PATH: -84.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between PATH and SNPS?
Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.